Wikipedia

User:Mr. Ibrahem/Vandetanib

< User:Mr. Ibrahem
Mr. Ibrahem/Vandetanib
Clinical data
Trade namesCaprelsa
Other namesZD6474
AHFS/Drugs.comMonograph
MedlinePlusa611037
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth[1]
Drug classKinase inhibitor[1]
Legal status
Legal status
Pharmacokinetic data
Protein binding90–96%
MetabolismCYP3A4, FMO1, FMO3
Elimination half-life19 days (mean)[2]
Excretion44% faeces, 25% urine
Identifiers
  • N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
Chemical and physical data
FormulaC22H24BrFN4O2
Molar mass475.362 g·mol−1
3D model (JSmol)
  • CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br
  • InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27) checkY
  • Key:UHTHHESEBZOYNR-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication used to treat a type of thyroid cancer, specifically medullary thyroid cancer.[1] It increases the amount of time before the disease worsens.[1] It is taken by mouth.[1]

Common side effects include acne, high blood pressure, headache, low calcium, low blood sugar, and diarrhea.[1] Other side effects include QT prolongation, sun sensitivity, hair loss, swelling, and corneal deposits.[1][3] Use during pregnancy or breastfeeding may harm the baby.[4] It works as a kinase inhibitor, mainly of the vascular endothelial growth factor receptor 2 (VEGFR2) and the epidermal growth factor receptor (EGFR).[5]

Vandetanib was approved for medical use in the United States in 2011.[1] In the United Kingdom it costs the NHS £5,000 per month as of 2020.[3] In the United States this amount costs about 16,000 USD as of 2021;[6] while in Canada it cost about 5,900 CAD per month as of 2017.[7]

References

edit
  1. ^ a b c d e f g h i j k l "Vandetanib Monograph for Professionals". Drugs.com. Archived from the original on 24 July 2012. Retrieved 6 August 2021.
  2. ^ a b "Caprelsa- vandetanib tablet, film coated". DailyMed. 19 June 2020. Archived from the original on 27 October 2020. Retrieved 8 December 2020.
  3. ^ a b c BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1061. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  4. ^ "Vandetanib (Caprelsa) Use During Pregnancy". Drugs.com. Archived from the original on 29 October 2020. Retrieved 6 August 2021.
  5. ^ "Definition of vandetanib". NCI Drug Dictionary. National Cancer Institute. 2011-02-02. Archived from the original on 2018-01-24. Retrieved 2021-05-02.
  6. ^ "Caprelsa Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 27 August 2021. Retrieved 6 August 2021.
  7. ^ "pCODR Expert Review Committee Final Recommendation" (PDF). CADTH. Archived (PDF) from the original on 19 October 2018. Retrieved 6 August 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Vandetanib&oldid=1233642635"